The ribosomal S6 kinase 2 (RSK2), also known as p90 ribosomal S6 kinase 3 (RPS6KA3), is a serine/threonine kinase within the RSK family, activated by the ERK/MAPK signaling pathway. It plays a critical role in regulating cell growth, survival, and differentiation by phosphorylating substrates like CREB, histone H3. and Bad. RSK2 dysfunction is linked to Coffin-Lowry syndrome, a rare genetic disorder characterized by intellectual disability and skeletal abnormalities, underscoring its importance in neural and developmental processes. RSK2 antibodies are essential tools for studying its expression, activation (e.g., phosphorylation at specific residues like Ser227/Thr577), and interactions in diseases such as cancer, where RSK2 often promotes tumor progression. These antibodies are typically validated for applications like Western blotting, immunofluorescence, and immunohistochemistry. Researchers rely on RSK2 antibodies to investigate signaling crosstalk, therapeutic targeting, and disease mechanisms. Specificity is ensured using knockout controls or peptide blocking, as RSK isoforms (RSK1-4) share structural homology. Commercial RSK2 antibodies are often raised in rabbits or mice against unique epitopes in the N- or C-terminal kinase domains. Proper sample preparation, including phosphatase inhibitors, is critical to preserve phosphorylation states during analysis.